Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-SELECT study of luseogliflozin versus DPP-4 inhibitors in type 2 diabetes mellitus
jRCTs031180241Completed
- Sponsor
- Soiken Holdings
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of luseogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Soiken Holdings. Primary endpoint: Composite endpoint achievement at week 52. Started Feb 2018; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031180241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180241.